Xeureka Held the Second Executive Board Meeting of Tokyo-1

On December 9, 2024, the second Executive Board Meeting of Tokyo-1 was held at the headquarters of Mitsui & Co.. Executives from Astellas Pharma, Ono Pharmaceutical, Daiichi Sankyo, and NVIDIA, as well as representatives from the Ministry of Economy, Trade and Industry (METI), participated in the event, where an active exchange of opinions took place.
During the first session, METI offered opening remarks and NVIDIA presented leading examples of progress being made globally in the field of AI drug discovery. Additionally, Xeureka provided a report on the activities of Tokyo-1 and shared results from joint validation studies conducted by participating companies.
The second session was conducted as a networking event, where executives from the pharmaceutical companies presented the outcomes of their involvement with Tokyo-1. Interview videos of researchers from companies involved in Tokyo-1 were also shown, offering attendees a chance to witness the passion and commitment of those researchers directly working with Tokyo-1.
The pharmaceutical company executives expressed high expectations for the initiatives coming out of Tokyo-1, including joint community activities in non-competitive areas such as validation studies, as a key asset in keeping up with the rapidly accelerating global trends in AI drug discovery.
The Tokyo-1 Executive Board is scheduled to meet regularly going forward. At the next meeting, the latest global trends in AI drug discovery will be shared, and participating pharmaceutical companies will present further results from their use of Tokyo-1.
Leveraging the ideas generated through the exchange of opinions among the executive members, Tokyo-1 will aim to become a leading innovation hub within the Japanese healthcare industry, with an initial focus on drug discovery.